Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Cash from Operations (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Cash from Operations data on record, last reported at 2484000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 56.47% year-over-year to 2484000.0; the TTM value through Dec 2025 reached 18012000.0, up 55.9%, while the annual FY2025 figure was 18012000.0, 55.9% up from the prior year.
  • Cash from Operations reached 2484000.0 in Q4 2025 per TLSI's latest filing, up from 3709000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 425954.0 in Q1 2022 and bottomed at 22880298.0 in Q3 2022.
  • Average Cash from Operations over 4 years is 8859125.0, with a median of 8743500.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: crashed 2365.76% in 2023, then surged 65.81% in 2025.
  • A 4-year view of Cash from Operations shows it stood at 8310000.0 in 2022, then decreased by 10.43% to 9177000.0 in 2023, then surged by 37.81% to 5707000.0 in 2024, then surged by 56.47% to 2484000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 2484000.0 in Q4 2025, 3709000.0 in Q3 2025, and 7320000.0 in Q2 2025.